Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Composition Gradient Light Scattering System

By Drug Discovery Trends Editor | September 30, 2009

calypsoWyatt Technology Corporation, a leader in absolute macromolecular characterization instrumentation and software, announces the availability of a new application note demonstrating the advanced capability of Composition Gradient Multi-angle Light Scattering (CG-MALS) technology. The experiment assessed the performance of Wyatt Technology’s Calypso automated composition gradient light scattering system for the evaluation of the inhibition efficacy of AEBSF, a small-molecule, irreversible inhibitor, on the self-association of the digestive enzyme ?-chymotrypsin. The Calypso is able to perform accurate and rapid analysis of inhibition kinetics of protein-protein binding as well as equilibrium association properties. The new application note, entitled “Inhibition Kinetics of Protein-Protein Binding with Calypso”, is available to download free-of-charge via www.wyatt.com.

CG-MALS is a powerful, non-destructive method for efficient characterization of macromolecular interactions without labeling, immobilization or additional biochemical substrates. It employs a series of samples of different composition or concentration in order to characterize reversible self- and hetero-association of proteins, reaction rates and affinities of aggregation or dissociation and non-specific, repulsive or attractive macromolecular interactions. The Calypso offers superior analytical capabilities, simplifying and automating CG-MALS measurements. The system’s automation enhances productivity by improving repeatability and reliability, while minimizing time and effort. The Calypso offers many advantages over other biophysical techniques for characterizing protein interactions, providing fast and accurate results.

The new application note describes the CG-MALS method using the Calypso automated composition gradient system. The instrument is used in conjunction with Wyatt Technology’s DAWN-HELEOS and miniDAWN-TREOS MALS detectors and an optional dRI or UV absorption on-line concentration detector. Experimental results demonstrate that the dissociation rate is dependent on the concentrations of protein and inhibitor, determining both the protein-inhibitor kinetics parameter kM and protein homodimer dissociation constant Kd.

Wyatt Technology Corporation


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE